Literature DB >> 19917886

Priming with angiopoietin-1 augments the vasculogenic potential of the peripheral blood stem cells mobilized with granulocyte colony-stimulating factor through a novel Tie2/Ets-1 pathway.

Min-Seok Kim1, Choon-Soo Lee, Jin Hur, Hyun-Jai Cho, Soo-In Jun, Tae-Youn Kim, Sae-Won Lee, Jung-Won Suh, Kyung-Woo Park, Hae-Young Lee, Hyun-Jae Kang, Dong-Soo Lee, Gou-Young Koh, Hironori Nakagami, Ryuichi Morishita, Young-Bae Park, Hyo-Soo Kim.   

Abstract

BACKGROUND: The low engraftment rate of stem/progenitor cells infused via the intracoronary route to the ischemic myocardium is one of the most important factors limiting the efficacy of cell therapy. We investigated the concept of priming peripheral blood stem cells enriched by granulocyte colony-stimulating factor mobilization and apheresis ((mob)PBSCs) with angiopoietin-1 (Ang1), to enhance the engraftment into the ischemic tissue and neovasculogenic potential. METHODS AND
RESULTS: The expression of Tie2, the Ang1 receptor, was significantly higher in (mob)PBSCs than naïve peripheral blood mononuclear cells (19.2+/-3.0% versus 1.2+/-0.8% versus 1.2+/-0.2%; P<0.001 for (mob)PBSCs from acute myocardial infarction (AMI) patients with granulocyte colony-stimulating factor treatment for 3 days versus peripheral blood mononuclear cells from AMI patients versus peripheral blood mononuclear cells from stable angina patients). After 4 hours of cartilage oligomeric matrix protein (COMP)-Ang1 stimulation, (mob)PBSCs committed to the endothelial lineage with the induction of CD31 and VE-cadherin expression, mediated by Tie2/Ets-1 pathway. Priming of (mob)PBSCs with COMP-Ang1 induced the expression of alpha4beta1 and alpha5beta1 integrins, which are also Ets-1 downstream molecules, leading to enhanced adhesion to endothelial cells or fibronectin. In a rabbit ear ischemia/reperfusion model, priming of (mob)PBSCs with COMP-Ang1 improved first-pass engraftment to the distal vascular bed after intraarterial delivery. In a murine ischemic hind-limb model, intravascular delivery of primed (mob)PBSCs enhanced both engraftment and neovascularization.
CONCLUSIONS: The short-term priming with COMP-Ang1 may be a feasible and promising option to activate (mob)PBSCs by enhancing differentiation and adhesiveness and to improve the efficacy of cell therapy for ischemic diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917886     DOI: 10.1161/CIRCULATIONAHA.109.856815

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Efficacious and clinically relevant conditioned medium of human adipose-derived stem cells for therapeutic angiogenesis.

Authors:  Suk Ho Bhang; Seahyoung Lee; Jung-Youn Shin; Tae-Jin Lee; Hyeon-Ki Jang; Byung-Soo Kim
Journal:  Mol Ther       Date:  2013-01-13       Impact factor: 11.454

2.  MCP-1-induced protein promotes endothelial-like and angiogenic properties in human bone marrow monocytic cells.

Authors:  Jianli Niu; Kangkai Wang; Olga Zhelyabovska; Yasser Saad; Pappachan E Kolattukudy
Journal:  J Pharmacol Exp Ther       Date:  2013-09-05       Impact factor: 4.030

3.  Evidence for critical role of Tie2/Ang1 interaction in metastatic oral cancer.

Authors:  Daisuke Kitajima; Atsushi Kasamatsu; Dai Nakashima; Isao Miyamoto; Yasushi Kimura; Yosuke Endo-Sakamoto; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

4.  Ultraviolet B preconditioning enhances the hair growth-promoting effects of adipose-derived stem cells via generation of reactive oxygen species.

Authors:  Yun-Mi Jeong; Young Kwan Sung; Wang-Kyun Kim; Ji Hye Kim; Mi Hee Kwack; Insoo Yoon; Dae-Duk Kim; Jong-Hyuk Sung
Journal:  Stem Cells Dev       Date:  2012-08-13       Impact factor: 3.272

5.  Gene control of tyrosine kinase TIE2 and vascular manifestations of infections.

Authors:  Chandra C Ghosh; Sascha David; Ruyang Zhang; Anthony Berghelli; Katelyn Milam; Sarah J Higgins; Jon Hunter; Aditi Mukherjee; Yongyue Wei; Mei Tran; Freeman Suber; Lester Kobzik; Kevin C Kain; Shulin Lu; Ansgar Santel; Kiichiro Yano; Prajna Guha; Daniel J Dumont; David C Christiani; Samir M Parikh
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-16       Impact factor: 11.205

6.  TIE2-expressing monocytes/macrophages regulate revascularization of the ischemic limb.

Authors:  Ashish S Patel; Alberto Smith; Silvia Nucera; Daniela Biziato; Prakash Saha; Rizwan Q Attia; Julia Humphries; Katherine Mattock; Steven P Grover; Oliver T Lyons; Luca G Guidotti; Richard Siow; Aleksandar Ivetic; Stuart Egginton; Matthew Waltham; Luigi Naldini; Michele De Palma; Bijan Modarai
Journal:  EMBO Mol Med       Date:  2013-05-07       Impact factor: 12.137

7.  Granulocyte-derived cationic Peptide enhances homing and engraftment of bone marrow stem cells after transplantation.

Authors:  Hakmo Lee; Jeong-Hwan Che; Jae-Chul Lee; Sung Soo Chung; Hye Seung Jung; Kyong Soo Park
Journal:  Lab Anim Res       Date:  2011-06-22

8.  COMP-Ang1 Potentiates EPC Treatment of Ischemic Brain Injury by Enhancing Angiogenesis Through Activating AKT-mTOR Pathway and Promoting Vascular Migration Through Activating Tie2-FAK Pathway.

Authors:  Hyo Eun Moon; Kyunghee Byun; Hyung Woo Park; Jin Hyun Kim; Jin Hur; Joong Shin Park; Jong Kwan Jun; Hyo-Soo Kim; Seung Leal Paek; In Keyoung Kim; Jae Ha Hwang; Jin Wook Kim; Dong Gyu Kim; Young Chul Sung; Gou-Young Koh; Chang W Song; Bonghee Lee; Sun Ha Paek
Journal:  Exp Neurobiol       Date:  2015-03-13       Impact factor: 3.261

9.  You can teach an old dog new tricks: angiopoietin-1 instructs Tie2(pos) myeloid cells to promote neovascularization in ischemic limbs.

Authors:  Costanza Emanueli; Nicolle Kränkel
Journal:  EMBO Mol Med       Date:  2013-06       Impact factor: 12.137

10.  Hypoxia-induced endothelial progenitor cell function is blunted in angiotensinogen knockout mice.

Authors:  Jin-Hwa Choi; Minh-Phuong Nguyen; Dongjin Lee; Goo-Taeg Oh; You-Mie Lee
Journal:  Mol Cells       Date:  2014-06-18       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.